ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
Dow Jones
40.003,59
0,34%
Euro vs US Dollar
1,0872
0,04%
Bitcoin
66.932,91
2,60%
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Beam Therapeutics Inc (BEAM)

  7. Beam Therapeutics Inc (BEAM) News

BEAM

Beam Therapeutics (BEAM)

Beam Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:BEAM
DatumZeitQuelleÜberschriftSymbolFirma
14/05/202422h00GlobeNewswire Inc.Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid CongressNASDAQ:BEAMBeam Therapeutics Inc
08/05/202412h30GlobeNewswire Inc.Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare ConferenceNASDAQ:BEAMBeam Therapeutics Inc
07/05/202413h19Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BEAMBeam Therapeutics Inc
07/05/202413h09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BEAMBeam Therapeutics Inc
07/05/202412h30GlobeNewswire Inc.Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial ResultsNASDAQ:BEAMBeam Therapeutics Inc
26/03/202411h30GlobeNewswire Inc.Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)NASDAQ:BEAMBeam Therapeutics Inc
28/02/202412h30GlobeNewswire Inc.Beam Therapeutics to Participate in Upcoming March 2024 Investor ConferencesNASDAQ:BEAMBeam Therapeutics Inc
27/02/202413h40Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:BEAMBeam Therapeutics Inc
27/02/202413h22Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:BEAMBeam Therapeutics Inc
27/02/202412h43Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BEAMBeam Therapeutics Inc
27/02/202412h30GlobeNewswire Inc.Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated MilestonesNASDAQ:BEAMBeam Therapeutics Inc
05/02/202412h30GlobeNewswire Inc.Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceNASDAQ:BEAMBeam Therapeutics Inc
02/02/202422h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BEAMBeam Therapeutics Inc
02/02/202422h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BEAMBeam Therapeutics Inc
02/02/202422h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BEAMBeam Therapeutics Inc
02/02/202422h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BEAMBeam Therapeutics Inc
02/02/202422h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BEAMBeam Therapeutics Inc
31/01/202422h47Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BEAMBeam Therapeutics Inc
08/01/202412h55Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BEAMBeam Therapeutics Inc
08/01/202412h30GlobeNewswire Inc.Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated MilestonesNASDAQ:BEAMBeam Therapeutics Inc
05/01/202422h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BEAMBeam Therapeutics Inc
02/01/202412h30GlobeNewswire Inc.Beam Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:BEAMBeam Therapeutics Inc
14/12/202322h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BEAMBeam Therapeutics Inc
14/12/202312h30GlobeNewswire Inc.Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of DirectorsNASDAQ:BEAMBeam Therapeutics Inc
20/11/202322h20Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BEAMBeam Therapeutics Inc
08/11/202313h30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BEAMBeam Therapeutics Inc
08/11/202313h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BEAMBeam Therapeutics Inc
08/11/202312h30GlobeNewswire Inc.Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial ResultsNASDAQ:BEAMBeam Therapeutics Inc
08/11/202312h30GlobeNewswire Inc.Beam Therapeutics to Participate in 2023 Jefferies London Healthcare ConferenceNASDAQ:BEAMBeam Therapeutics Inc
01/11/202321h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BEAMBeam Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:BEAM

Kürzlich von Ihnen besucht

NASDAQ
FEOSHX
Smid Capital Strength Po...
FX
TWDSEK
TWD vs SEK
NASDAQ
BIDZ
COIN
XPRTUST
Persistence
BIT
F38737
Vontobel Financial Produ...
LSE
AH81
Lloyds Bk.25
ASX
MQA
BOV
TECN3Q
TECHNOS ON
LSE
PGHZ
Pcgh Zdp
LSE
55AM
Absa Ltd 26
EU
ALAGR
AGROGENERATION
BIT
UC4B0B
Unicredit Bank
BIT
UC277T
Unicredit Bank
COIN
CITYUST
Manchester City Fan Token
LSE
ZP62
Citi Fun 24
AMEX
DESC
Xtrackers Russell 2000 C...
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten